UBS Group’s ANACOR PHARMACEUTICALS INC COM ANAC Stock Holding History

UBS Group’s Portfolio ANAC Stock Details ANAC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	–	Sell	-84,057	Closed	-$4.49M	–	8460
2016 Q1	$4.49M	Buy	84,057 +5,635	+7%	+$416K	﹤0.01%	1958
2015 Q4	$8.86M	Sell	78,422 -38,438	-33%	-$4.23M	0.01%	1486
2015 Q3	$13.8M	Sell	116,860 -5,232	-4%	-$683K	0.01%	1145
2015 Q2	$9.45M	Sell	122,092 -4,266	-3%	-$280K	0.01%	1525
2015 Q1	$7.31M	Sell	126,358 -19,471	-13%	-$827K	0.01%	1730
2014 Q4	$4.7M	Buy	+145,829	New	+$4.38M	﹤0.01%	2142

Other funds holding ANAC

KCM

Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return

CIM

CIM Investment Management Pittsburgh, Pennsylvania $375M AUM 32.03% 1-Year Est. Return

UBS Group's ANAC Position: Q2 2016 in Review

UBS Group sold out of ANACOR PHARMACEUTICALS INC COM (ANAC) in Q2 2016, closing a stake of 84,057 shares — an estimated $4.49M sold.

UBS Group first reported a position in ANAC in Q4 2014 and held it in 6 quarters. The position peaked at $13.8M in Q3 2015. 2 funds tracked by Wall St. Rank hold ANAC as of Q2 2016.

UBS Group reported no remaining ANACOR PHARMACEUTICALS INC COM position as of Q2 2016 after selling out during the quarter.
UBS Group sold 84,057 ANACOR PHARMACEUTICALS INC COM shares in Q2 2016, an estimated $4.49M.
UBS Group first reported a position in ANACOR PHARMACEUTICALS INC COM in Q4 2014 and held it in 6 quarters.
UBS Group's ANACOR PHARMACEUTICALS INC COM position peaked at $13.8M in Q3 2015.
2 funds tracked by Wall St. Rank held ANACOR PHARMACEUTICALS INC COM as of Q2 2016.

Based on UBS Group's 13F filing for Q2 2016, filed 12 Aug 2016.